Clinical Trial Update: Evaluation of Liraglutide 3.0mg in Patients With Poor Weight-loss and a Suboptimal Glucagon-like Peptide-1 Response [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating liraglutide 3.0 mg in patients with poor weight loss and suboptimal GLP-1 response for obesity; completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• liraglutide 3.0 mg (liraglutide)

Snippet

Sponsor: University College, London | Conditions: Obesity | Phase 4 | Status: COMPLETED